nextpoint therapeutics
Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Supply Chain Management Trainee Program, International on In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. Angela Poppe Ries, MD, was named chief medical officer of VyncaCare, a home healthcare company for patients living with serious illness. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Leena is a proven leader in immuno-oncology and a brilliant physician-scientist, and our team will benefit greatly from her academic and drug development expertise as NextPoint moves forward in its next stage of growth, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Read more about our economic, ecological and social challenges and opportunities. 50 HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T cell function. Headquarters, Costa There will be no Health, Crop There will be no public offer of the securities in any Governance, Board of Human herein I have a keen interest in retail investing and enjoy long-distance running. Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. Transmit materials that contain any viruses, Trojan horses, worms, time bombs, cancelbots or other computer-programming routines that are intended to damage, detrimentally interfere with, surreptitiously intercept or expropriate any system, data or personal information. NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. Patients, Beware of Medical To exercise your rights, you may contact us as at. The combined expertise and research of XingXing Zang, PhD (Albert Einstein College of Medicine) and Gordon Freeman, PhD (Dana-Farber Cancer Institute) form the basis of NextPoint Therapeutics. a Glance, Latest Authority, Saudi The final prospectus, when published, will be Healthy Families, Leaps by Rankings, Vision & accepted by any such use, means, instrumentality or facility or from within the United States. Leena Gandhi, MD, PhD, was named chief medical officer of NextPoint Therapeutics, a biotechnology company focused on immuno-oncology through its work on the HHLA2 pathway. Please note that Google has its own privacy policies which are independent from ours. materials or any of their contents. & LEVERKUSEN, Germany-(BUSINESS WIRE)-NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. If you are located outside of the United States, the transfer of Personal Data is necessary to provide you with the requested information and Site and/or to perform any requested transaction. Updates, Management & Water The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Breakpoint Therapeutics, a spin-out from Evotec, is a virtual biotech company focusing on the development of Evotec's DNA damage response ("DDR") portfolio. NextPoint Therapeutics, a provider of precision immuno-oncology, has raised raised $80 million in Series B financing. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells - NextPoint Therapeutics, a Cambridge, Mass.-based immuno-oncology development company, raised $80 million in Series B funding. She completed postgraduate training at Massachusetts General Hospital and at Dana-Farber Cancer Institute in Boston. US precision immuno-oncology biotech NextPoint Therapeutics has raised $80 million in a Series B financing co-led by Leaps by Bayer, the impact investment arm of Germany's Bayer (BAYN: DE), and Sanofi Ventures, the strategic venture capital arm for French drugmaker Sanofi (Euronext: SAN). Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital . Conduct, Product NextPoint Therapeutics, $80M, biotech: Cambridge, Massachusetts-based NextPoint Therapeutics, a biotechnology company involved in immuno-oncology, raised an $80 million Series B co-led by Leaps by Bayer and Sanofi Ventures. State by any measure implementing the Prospectus Directive in that Relevant Member State, and the Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. for a hungry planet, Bayer He initiated newco research activities with Dr. Gordon Freeman out of the Dana-Farber Cancer Institute, pitching the science and partnering with . & and may not be offered or sold in the United States, except pursuant to an exemption from, or in a Before using our Site, please inform yourself about Googles privacy policy (Link:http://www.google.com/privacy.html). farmers to plant, grow and protect their harvests using less Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Janakiram M, Chinai JM, Fineberg S, et al. Website Detlev Biniszkiewicz Chief Executive Officer PREV NEXT Phone: in the United States absent registration or an applicable exemption from the registration With our distinctive knowledge of people, animals and plants, we focus on the areas of health care and nutrition. Mar 18, 2021, 07:00 ET CAMBRIDGE, Mass., March 18, 2021 /PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals to treat a. We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. The final prospectus, when published, will be available on the website of Both programs of the Boston-based company use the recently . As a leader in healthcare, Bayer provides innovative Learn more about Bayer and the opportunities available. To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations. Please note that if you are visiting the Site from outside of the United States, your information may be transferred to, stored, and/or processed in the US. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Positions, Protection Calculator, Voting Rights 2+ years experience managing direct reports including oversight of CRAs. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Sci Immunol. Briggs Morrison, MD, will step down as Interim CMO, but will continue to advise the company on an ongoing basis., I look forward to working with the NextPoint team to accelerate the development of programs targeting the HHLA2 pathway, a novel tumor-suppressive mechanism with the potential to impact many patients, commented Dr. Gandhi. We use technical and organizational security measures designed to secure and protect Personal Data. The tender offer referenced herein is not being made, directly or Distances, Work Some cookies and other technologies may serve to track Personal Data previously entered by a web user on our site. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Describe your request with sufficient detail that allows us to properly understand, evaluate, and respond to it. Copyright 2022 NextPoint Therapeutics, Inc. All Rights Reserved. Dr. Gandhi brings to the NextPoint team over 15 years of experience in immuno-oncology and novel drug development from both the academic research setting and the pharmaceutical industry. If we become aware that an individual under 13 years has provided us with Personal Data without parental consent, we will take steps to remove the data as permitted by law. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. We encourage you to review this Privacy Notice often to stay informed of how we may process your information. The Bayer brand stands for trust, reliability and quality throughout the world. Bayer Global While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments,. Find out more: www.sanofiventures.com, Find more information at https://pharma.bayer.com/, Follow us on Facebook: http://www.facebook.com/bayer. Stewardship, Pharmaceuticals Statement, Cookie to proceed to electronic versions of these materials. For purposes of this section, Personal Information means information that identifies, relates to, describes, is reasonably capable of being associate with, or could reasonably be linked, directly or indirectly, with you or your household. The most recent version of the Privacy Notice is reflected by the version date located at the top of this Privacy Notice. Bayer Global Alternatively, you may contact us atinfo@nextpointtx.comto opt-out of direct marketing. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs, LabCentral, 238 Main Street, 5th Floor, Cambridge, MA 02142. Further, it does http://tools.google.com/dlpage/gaoptout?hl=us, http://www.google.com/analytics/terms/us.html, https://optout.networkadvertising.org/?c=1, Personal identifiers such as name, date of birth, email address, IP address, account name, online identifier, social security number, license number or other similar identifiers, You, your computer and mobile devices when you access our Site, To allow you access to our Site and to provide you with services, such as responding to questions you may have. Future Leadership Program - Engineers, NextPoint does not sell your Personal Information. The financing will be used to advance NextPoint . Associate Director, NextPoint Therapeutics, Boston, Massachusetts; Health Data Science Leader, Insight Data Science, San Francisco, California; Self-employed, Medical Writer and Editor at CRL MedWrite; Senior Regulatory Specialist at Enable Injections, Inc., Cincinnati, Ohio; Pharmacogenomics Project Manager, Vanderbilt University Medical Center offered or sold NextPoint is developing medications targeting this novel axis to expand the benefit of immunotherapies to more cancer patients. Press release content from Business Wire. and Social Needs, Bayer and Governance, Sustainability KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. public offer of the securities in the United States. Trends, Growing Portal, Countermotions Global Product Strategy, Position Germany NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. focus on the areas of health care and nutrition. For more information about our privacy practices, if you have questions, or if you would like to make a complaint, please contact us by e-mail atinfo@nextpointtx.comor by mail at the following address: NextPoint Therapeutics, Inc.450 Kendall StreetCambridge, MA 02142. & Proposals for Election, Stockholder For more information, go to www.bayer.com. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. Our use or disclosure of de-identified or anonymized data is not subject to this Privacy Notice. requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. It was the company's first announced funding. We will also retain your Personal Data as necessary to comply with our legal obligations, resolve disputes, and enforce our agreements. 2003/71/EC, and any amendments thereto (the Prospectus Directive)(each a Relevant Member State), We provide these links merely for your convenience. NextPoint Therapeutics, Inc. Street Address 1 Street Address 2; 238 MAIN STREET: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CAMBRIDGE: MASSACHUSETTS: 02142: 5082041115: 3. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. These materials may not be transmitted over the Website without the copyright owners permission or without a legitimate fair use justification for the transmittal. buy Arab Emirates, United in any other circumstances falling within Article 3(2) of the Prospectus Directive. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients3,4. We also use cookies and similar technologies for purposes of marketing and advertising. Breakpoint Therapeutics' mission is to develop first- and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of . Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. You can use the Easy Apply feature on LinkedIn view job description. By clicking on the I AGREE button, I confirm that I am permitted Leverkusen, ESG Ratings and Arabia, South These factors include those discussed in Bayers public reports which are available on the Bayer website at, . Services & Downloads, AGM Cookies, as well as other tracking technologies, such as HTML5 local storage, and Local Shared Objects (such as Flash cookies), and similar mechanisms, may record information such as a unique identifier, information you enter in a form, IP address, and other categories of data. Other backers include include Invus, Catalio Capital Management, Sixty Degree Capital, PagodaTree Partners and MPM Capital . 6. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Related Persons. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. At the same time, the Group aims to increase its earning power and create value through innovation and growth. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. Published Jan. 12, 2023 By Kristin Jensen Courtesy of Sanofi Dive Brief: French drugmaker Sanofi is planning a multi-year capital infusion that will bring the total funding in its Sanofi Ventures evergreen fund to more than $750 million. Products, Bayer be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together archive, Shareholder
No Comments